Epidermal growth factor-dependent enhancement of invasiveness of squamous cell carcinoma of the breast

Cancer Science

Volumn 101, Issue 5, 2010, Pages 1133-1140

  Kimura, Fuyo ^a   Iwaya, Keiichi ^a,b   Kawaguchi, Tokuichi ^c   Kaise, Hiroshi ^a   Yamada, Kimito ^a   Mukai, Kiyoshi ^d   Matsubara, Osamu ^b   Ikeda, Norihiko ^a   Kohno, Norio ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

^b NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^c CANCER INSTITUTE   (Japan)

^d SAISEIKAI CENTRAL HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN RELATED PROTEIN 2; ACTIN RELATED PROTEIN 3; CORTACTIN; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; NEURAL WISKOTT ALDRICH SYNDROME PROTEIN;

ACTIN POLYMERIZATION; ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CANCER INVASION; CASE REPORT; CELL MIGRATION; CELL MOTILITY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; WESTERN BLOTTING;

BREAST NEOPLASMS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL PROLIFERATION; CORTACTIN; EPIDERMAL GROWTH FACTOR; FEMALE; HUMANS; NEOPLASM INVASIVENESS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 77953205675     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2010.01527.x     Document Type: Article

References (31)

1. Dent R, Trudeau M, Pritchard KI. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007, 13:4429-34.
2. Fulford LG, Easton DF, Reis-Filho JS. Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast. Histopathology 2006, 49:22-34.
3. Lien HC, Lin CW, Mao TL, Kuo SH, Hsiao CH, Huang CS. P53 overexpression and mutation in metaplastic carcinoma of the breast: genetic evidence for a monoclonal origin of both the carcinomatous and the heterogeneous sarcomatous components. J Pathol 2004, 204:131-9.
4. Toikkanen S. Primary squamous cell carcinoma of the breast. Cancer 1981, 48:1629-32.
5. Rekha EA, Reis-Filho JS, Ellis IO. Basal-like breast cancer: a critical review. J Clin Oncol 2008, 26:2568-81.
6. Nielsen TO, Hsu FD, Jensen K. Immunohistochemical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004, 10:5367-74.
7. Carey LA, Dees EC, Sawyer L. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007, 13:2329-34.
8. Sorlie T, Perou CM, Tibshirani R. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001, 98:10869-74.
9. Chen WT, Wang JY. Specialized surface protrusions of invasive cells, invadopodia and lamellipodia, have differential MT1-MMP, and TIMP-2 localization. Ann NY Acad Sci 1999, 878:361-71.
10. Muller SC, Chen WT. Cellular invasion into matrix beads: localization of beta 1 and integrins and fibronectin to the invadopodia. J Cell Sci 1991, 99:213-25.
11. Machesky LM, Mullins RD, Higgs HN. Scar, a WASp-related protein, activates nucleation of actin filaments by the Arp2/3 complex. Proc Natl Acad Sci U S A 1999, 96:3739-44.
12. Takenawa T, Miki H. WASP and WAVE family proteins: key molecules for rapid rearrangement of cortical actin filaments and cell movement. J Cell Sci 2001, 114:1801-9.
13. Sarmiento C, Wang W, Dovas A. WASP family members and formin proteins coordinate regulation of cell protrusions in carcinoma cells. J Cell Biol 2008, 180:1245-60.
14. Iwaya K, Kohno N, Mukai K. Coexpression of Arp2 and WAVE2 predicts poor outcome in invasive breast carcinoma. Mod Pathol 2007, 20:339-43.
15. Clark ES, Whigham AS, Yarbrough WG, Weaver AM. Cortactin is an essential regulator of matrix metalloproteinase secretion and extracellular matrix degradation in invadopodia. Cancer Res 2007, 67:4227-35.
16. Uruno T, Liu J, Zhang P. Activation of Arp2/3 complex-mediated actin polymerization by cortactin. Nat Cell Biol 2001, 3:259-66.
17. Li Y, Tondravi M, Liu J. Cortactin potentiates bone metastasis of breast cancer cells. Cancer Res 2001, 61:6906-11.
18. Hofman P, Butori C, Havet K. Prognostic significance of cortactin levels in head and neck squamous cell carcinoma: comparison with epidermal growth factor receptor status. Br J Cancer 2008, 98:956-64.
19. Satoh A, Takayama E, Kojima K. Expression of carbohydrate-binding protein p33/41 in human tumor cell lines. J Biochem 1996, 119:346-53.
20. Iwaya K, Tsuda H, Fujita S, Suzuki M, Hirohashi S. Natural state of mutant p53 protein and heat shock protein 70 in breast cancer tissues. Lab Invest 1995, 72:707-14.
21. Allred C, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 1998, 11:155-68.
22. Lo HW, Xia W, Wei Y, Ali-Seyed M, Huang SF, Hung MC. Novel prognostic value of nuclear epidermal growth factor receptor in breast cancer. Cancer Res 2005, 61:338-48.
23. Ellis IO, Cornelise CJ, Schnitt SJ. Invasive breast carcinoma. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Breast and Female Genital Organs 2003, 13-59. Tavassoli FA, Devilee P, In, eds, Lyon, IARC Press
24. Perou CM, Sorlie T, Eisen MB, van de Rijin M, Jeffrey SS, Rees CA. Molecular portraits of human breast tumours. Nature 2000, 406:747-52.
25. Yang Z, Bagheri-Yarmand R, Wang RA. The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 (Iressa) suppresses c-Src and Pak1 pathways and invasiveness of human cancer cells. Clin Cancer Res 2004, 10:658-67.
26. Klijn JG, Bems PM, Schmitz PI, Foekens JA. The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients. Endocr Rev 1992, 13:3-17.
27. Bhargava R, Gerald WL, Li AR. EGFR gene amplification in breast cancer: correlation with epidermal growth factor and Her-2 status and absence of EGFR-activating mutations. Mod Pathol 2005, 18:1027-33.
28. Timpson P, Wilson AS, Lehrbach GM, Sutherland RL, Musgrove EA, Daly RJ. Aberrant expression of cortactin in head and neck squamous cell carcinoma cells is associated with enhanced cell proliferation and resistance to the epidermal growth factor receptor inhibitor gefitinib. Cancer Res 2007, 67:9304-14.
29. Wu H, Montone KT. Cortactin localization in actin-containing adult and fetal tissues. J Histochem Cytochem 1998, 46:1189-91.
30. Bryce NS, Clark ES, Leysath JL, Currie JD, Webb DJ, Weaver AM. Cortactin promotes cell motility by enhancing lamellipodial persistence. Curr Biol 2005, 15:1276-85.
31. Kowalski JR, Egile C, Gil S. Cortactin regulates cell migration through activation of N-WASP. J Cell Sci 2005, 118:79-87.